The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma.
- DOI
- 10.1016/j.eururo.2022.10.010
- Published
- 2023 Jan
- Container
- European urology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.eururo.2022.10.010,
title = {The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma.},
author = {Bedke J and Albiges L and Capitanio U and Giles RH and Hora M and Ljungberg B and Marconi L and Klatte T and Volpe A and Abu-Ghanem Y and Dabestani S and Fernández-Pello S and Hofmann F and Kuusk T and Tahbaz R and Powles T and Bex A},
year = {2023},
journal = {European urology},
doi = {10.1016/j.eururo.2022.10.010},
url = {https://doi.org/10.1016/j.eururo.2022.10.010}
}RIS
TY - JOUR TI - The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma. AU - Bedke J AU - Albiges L AU - Capitanio U AU - Giles RH AU - Hora M AU - Ljungberg B AU - Marconi L AU - Klatte T AU - Volpe A AU - Abu-Ghanem Y AU - Dabestani S AU - Fernández-Pello S AU - Hofmann F AU - Kuusk T AU - Tahbaz R AU - Powles T AU - Bex A PY - 2023 JO - European urology DO - 10.1016/j.eururo.2022.10.010 UR - https://doi.org/10.1016/j.eururo.2022.10.010 ER -
APA
J, B., L, A., U, C., RH, G., M, H., B, L., L, M., T, K., A, V., Y, A., S, D., S, F., F, H., T, K., R, T., T, P., & A, B. (2023). The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma.. European urology. https://doi.org/10.1016/j.eururo.2022.10.010
Source records
- pubmed · retrieved 2026-09-26T00:18:01.111Z